Ivabradine Krka

Ivabradine, the active ingredient in Ivabradine Krka, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate by selectively inhibiting the funny current in the sinoatrial node and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ivabradine acts on the cardiac conduction system by selectively inhibiting the If current, and is used in specific cardiovascular conditions.

- Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Heart failure with reduced ejection fraction: lowers heart rate and may improve clinical outcomes in NYHA class II–III patients. - Symptomatic coronary artery disease despite optimal therapy: provides additional heart‑rate control when beta‑blockers are insufficient.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Luminous phenomena (phosphenes): transient visual sensations, especially in low light. - Headache: mild to moderate intensity. - Dizziness or fatigue: often related to reduced heart rate.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Symptomatic hypotension or syncope.

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

- Assess baseline heart rate: ensure resting HR ≥ 50 bpm before starting. - Monitor for symptomatic bradycardia: discontinue if HR < 40 bpm or if patient experiences dizziness. - Avoid use in acute decompensated heart failure or unstable angina. - Caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant strong CYP3A4 inhibitors without dose modification. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ivabradine plasma levels. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Sotalol: combined use may precipitate severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose reduction. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): can reduce ivabradine efficacy. - Certain antidepressants affecting CYP3A4 (e.g., sertraline): monitor heart rate and adjust if needed.